Drugs that inhibit α-synuclein
An anti-α-synuclein drug , or an α-synuclein inhibitor , is a drug which blocks or inhibits α-synuclein . α-Synuclein is a protein which is thought to be involved in the development and progression of α-synucleinopathies including Parkinson's disease , dementia with Lewy bodies , and multiple system atrophy . Anti-α-synuclein drugs are under development for treatment of Parkinson's disease and other α-synuclein-related diseases. Examples include the monoclonal antibodies prasinezumab and cinpanemab , which both failed to show effectiveness in slowing the progression of Parkinson's disease in phase 2 clinical trials . Other anti-α-synuclein drugs, like the monoclonal antibody exidavnemab , the α-synuclein vaccines PD01A and PD03A , and the small-molecule α-synuclein misfolding and aggregation inhibitors minzasolmin and emrusolmin , are also under development. Memantine is also being studied as a potential disease-modifying treatment for Parkinson's disease by inhibiting cell-to-cell transmission of α-synuclein and is in a phase 3 trial for this purpose.
See also
References
^ Noguchi-Shinohara M, Ono K (June 2023). "The Mechanisms of the Roles of α-Synuclein, Amyloid-β, and Tau Protein in the Lewy Body Diseases: Pathogenesis, Early Detection, and Therapeutics" . Int J Mol Sci . 24 (12): 10215. doi :10.3390/ijms241210215 . PMC 10298861 . PMID 37373401 .
^ Knecht L, Folke J, Dodel R, Ross JA, Albus A (September 2022). "Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective" . Neurotherapeutics . 19 (5): 1489–1502. doi :10.1007/s13311-022-01288-7 . PMC 9606184 . PMID 36083395 .
Zampar S, Di Gregorio SE, Grimmer G, Watts JC, Ingelsson M (2024). ""Prion-like" seeding and propagation of oligomeric protein assemblies in neurodegenerative disorders" . Front Neurosci . 18 : 1436262. doi :10.3389/fnins.2024.1436262 . PMC 11330897 . PMID 39161653 .
Fleming SM, Davis A, Simons E (January 2022). "Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies" . Neuropharmacology . 202 : 108870. doi :10.1016/j.neuropharm.2021.108870 . PMC 10251253 . PMID 34742741 .
Grosso Jasutkar H, Oh SE, Mouradian MM (January 2022). "Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease" . Pharmacol Rev . 74 (1): 207–237. doi :10.1124/pharmrev.120.000133 . PMC 11034868 . PMID 35017177 .
McFarthing K, Rafaloff G, Baptista M, Mursaleen L, Fuest R, Wyse RK, Stott SR (2022). "Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update" . Journal of Parkinson's Disease . 12 (4): 1073–1082. doi :10.3233/JPD-229002 . PMC 9198738 . PMID 35527571 .
Categories :
Anti-α-synuclein drug
Add topic
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
**DISCLAIMER** We are not affiliated with Wikipedia, and Cloudflare.
The information presented on this site is for general informational purposes only and does not constitute medical advice.
You should always have a personal consultation with a healthcare professional before making changes to your diet, medication, or exercise routine.
AI helps with the correspondence in our chat.
We participate in an affiliate program. If you buy something through a link, we may earn a commission 💕
↑
